Currently out of the existing stock ratings of James Edwardes Jones, 10 are a HOLD (17.24%), 45 are a BUY (77.59%), 3 are a SELL (5.17%).

James Edwardes Jones

Work Performance Price Targets & Ratings Chart

Analyst James Edwardes Jones, currently employed at RBC, carries an average stock price target met ratio of 34.54% that have a potential upside of 26.69% achieved within 83 days. Previously, James Edwardes Jones worked at OPPENHEIMER.

James Edwardes Jones’s has documented 105 price targets and ratings displayed on 18 stocks. The coverage is on Consumer Defensive, Healthcare sectors.

Most recent stock forecast was given on PLRX, Pliant Therapeutics at 10-Aug-2023.

Wall Street Analyst James Edwardes Jones

Analyst best performing recommendations are on CYCC (CYCLACEL PHARMACEUTICALS).
The best stock recommendation documented was for CYCC (CYCLACEL PHARMACEUTICALS) at 3/7/2023. The price target of $10 was fulfilled within 3 days with a profit of $0.93 (8.51%) receiving and performance score of 28.36.

Average potential price target upside

of $15.32 (31.99%) on RXDX (PROMETHEUS BIOSCIENCES).
of $14.78 (75.87%) on VTYX (VENTYX BIOSCIENCES).
of $14.27 (197.02%) on CRBP (CORBUS PHARMACEUTICALS).

BTI British American Tobacco p.l.c. BUD Anheuser Busch Inbev NV ADR DEO Diageo PLC ADR UL Unilever PLC ADR RXDX Prometheus Biosciences CMMB Chemomab Therapeutics Ltd DRC CYCC Cyclacel Pharmaceuticals EVAX Evaxion Biotech AS MBRX Moleculin Biotech PDRDY Pernod Ricard SA PLRX Pliant Therapeutics PMVP Pmv Pharmaceuticals UN Unilever PLC VTYX Ventyx Biosciences NOVN Novan CRBP Corbus Pharmaceuticals PNT POINT Biopharma Global RAIN Rain Therapeutics

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score